Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant

NCT01321541 is registered in ClinicalTrials.gov with CTI BioPharma as lead sponsor.

NCT NCT01321541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01321541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Lead sponsor
CTI BioPharma
Phase
Phase 3
Overall status
Completed
Start date
April 20, 2011
Completion date
September 14, 2018
Enrollment
312 (actual)
Sites
131

Conditions

As the registry lists them; a condition with its own page is linked.

de novo dlbcl, diffuse large b-cell lymphoma, dlbcl transformed from indolent lymphoma, follicular grade 3 lymphoma